16.12.2024 07:00:18
|
Large-scale SPPS capacity in Braine-l’Alleud starts production
PolyPeptide Group
/ Key word(s): Miscellaneous
Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the new large-scale SPPS capacity at its manufacturing site in Braine-l’Alleud, Belgium. Following the completion of construction and thorough testing, PolyPeptide commissioned its new solid-phase peptide synthesis (SPPS) capacity in Braine l’Alleud and started production, with the ramp-up planned throughout 2025. The capacity supports the multi-year commercial agreement announced previously in December 2022. The agreement has an annual order value of around EUR 100 million after the ramp-up phase. To ensure high productivity, the new facility combines PolyPeptide’s proprietary manufacturing technology with an integrated engineering design and advanced automation and process control. Closed material flows and reduced solvent consumption contribute to improved sustainability. Over the last three years, PolyPeptide invested around EUR 100 million into the new capacity. Its start of production is consistent with the guidance for 2024, and the mid-term outlook communicated by PolyPeptide on 13 August 2024. Juan José González, CEO of PolyPeptide: “This project is the largest single investment in PolyPeptide’s 70-year history. The start of production is the result of the successful collaboration with our GLP-1 customer over several years. In parallel to the ramp-up ahead of us, we are pursuing our growth strategy with further GLP-1 capacity investments that combine innovative manufacturing technologies with the potential of modularity.”
Contact PolyPeptide Group AG Michael Stäheli Head of Investor Relations & Corporate Communications michael.staeheli@polypeptide.com T: +41 43 502 0580
About PolyPeptide PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com. @PolyPeptide – follow us on LinkedIn Disclaimer This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. In particular, the statements related to the guidance for 2024 and mid-term outlook constitute forward-looking statements and are not guarantees of future financial performance. The Group’s actual results of operations could deviate materially from those set forth in the guidance for 2024 and mid-term outlook. As such, investors should not place undue reliance on the statements related to the guidance for 2024 and mid-term outlook. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
End of Media Release |
Language: | English |
Company: | PolyPeptide Group |
Neuhofstrasse 24 | |
6340 Baar | |
Switzerland | |
Phone: | +41435020580 |
E-mail: | mediateam@polypeptide.com |
Internet: | www.polypeptide.com |
ISIN: | CH1110760852 |
Valor: | 111076085 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2051091 |
End of News | EQS News Service |
|
2051091 16.12.2024 CET/CEST
Nachrichten zu PolyPeptide
07:00 |
Grossvolumige SPPS-Kapazität in Braine-l’Alleud startet Produktion (EQS Group) | |
07:00 |
Large-scale SPPS capacity in Braine-l’Alleud starts production (EQS Group) | |
13.12.24 |
SPI-Titel PolyPeptide-Aktie: So viel hätten Anleger an einem PolyPeptide-Investment von vor 3 Jahren verloren (finanzen.ch) | |
06.12.24 |
SPI-Papier PolyPeptide-Aktie: So viel hätte eine Investition in PolyPeptide von vor einem Jahr abgeworfen (finanzen.ch) | |
26.11.24 |
Schwacher Handel: SPI verliert (finanzen.ch) | |
15.11.24 |
SPI-Papier PolyPeptide-Aktie: So viel Verlust hätte ein Investment in PolyPeptide von vor 3 Jahren bedeutet (finanzen.ch) | |
08.11.24 |
SPI-Titel PolyPeptide-Aktie: So viel Gewinn hätte eine Investition in PolyPeptide von vor einem Jahr abgeworfen (finanzen.ch) | |
01.11.24 |
Börse Zürich in Grün: SPI schlussendlich im Aufwind (finanzen.ch) |
Die Assetklasse Private Debt erklärt | BX Swiss TV
Private Debt: Die rasant wachsende Anlageklasse mit grossem Potenzial für Investoren und Unternehmen!
Im Experteninterview mit Kirsten Bode von Muzinich & Co und Olivia Hähnel von der BX Swiss erfahren Sie, warum Private Debt eine spannende Alternative zur traditionellen Kreditfinanzierung ist. Die Anlageklasse ermöglicht Investoren eine sinnvolle Diversifikation, bietet attraktive Illiquiditätsprämien und zeichnet sich durch eine geringe Volatilität aus. Gleichzeitig profitieren mittelständische Unternehmen von flexiblen Finanzierungslösungen, um Wachstum und Projekte voranzutreiben. Insbesondere in Europa hat sich der Markt in den letzten zehn Jahren verdreifacht und bietet über neue Fondsmodelle auch Privatanlegern Zugang. 2025 könnte ein entscheidendes Jahr für Private Debt werden – dank sinkender Zinsen und steigender Nachfrage. Ein absolutes Muss für alle, die ihre Anlagestrategie um zukunftsträchtige Optionen erweitern wollen!
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Notenbanken im Fokus: SMI im Minus -- DAX tiefer -- Asiens Börsen schließen in RotDer heimische und der deutsche Aktienmarkt präsentieren sich mit Verlusten zum Wochenstart. Die asiatischen Börsen zeigten sich am Montag schwächer.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |